Last reviewed · How we verify
NCT03944902: BRCA
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Phase 1 trial testing Cohort 1: Dose Escalation in Ovarian Cancer in 1 participant. Terminated before completion.
5 January 2022
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 1 September 2021 |
| Primary completion | 5 January 2022 |
| Estimated completion | 5 January 2022 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Cohort 1: Dose Escalation — full drug profile →
- Cohort 2: Dose Escalation
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Resistant BRCA Wild-Type Ovarian Cancer — all drugs for Resistant BRCA Wild-Type Ovarian Cancer →
Sponsor
University of Alabama at Birmingham
Who can join
18 and older, female only, with Ovarian Cancer or Resistant BRCA Wild-Type Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to investigate the efficacy of the combination of CB-839 with Niraparib in platinum resistant BRCA wild-type ovarian cancer patients. The primary and secondary objectives are to determine the maximum tolerated dose of CB-839 in combination with Niraparib and to determine the response rate and percentage of participants who remain progression free at 6 months.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
Yang WH, Qiu Y, Stamatatos O, Janowitz T, et al · · 2021 · cited 222× · PMID 34020912 · DOI 10.1016/j.trecan.2021.04.003 -
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.
Jin P, Jiang J, Zhou L, Huang Z, et al · · 2022 · cited 180× · PMID 35851420 · DOI 10.1186/s13045-022-01313-4 -
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle.
Wang B, Pei J, Xu S, Liu J, et al · · 2024 · cited 81× · PMID 38459595 · DOI 10.1186/s13046-024-02994-0 -
Metabolic Regulation of Redox Balance in Cancer.
Purohit V, Simeone DM, Lyssiotis CA. · · 2019 · cited 79× · PMID 31288436 · DOI 10.3390/cancers11070955 -
Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment.
Shen YA, Chen CL, Huang YH, Evans EE, et al · · 2021 · cited 61× · PMID 33721588 · DOI 10.1016/j.cbpa.2021.01.006 -
Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells.
Li X, Zhu H, Sun W, Yang X, et al · · 2021 · cited 48× · PMID 34503536 · DOI 10.1186/s12935-021-02121-5 -
Thiadiazole derivatives as anticancer agents.
Szeliga M. · · 2020 · cited 41× · PMID 32880874 · DOI 10.1007/s43440-020-00154-7 -
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.
Ni R, Li Z, Li L, Peng D, et al · · 2023 · cited 38× · PMID 36959802 · DOI 10.3389/fonc.2023.1143798
Verify or expand the search:
- PubMed search for NCT03944902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03944902 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03944902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing